INITIAL RESULTS OF TREATMENT OF HIGH-GRADE GLIOMA AT VIETNAM NATIONAL CANCER HOSPITAL

Trần Anh Đức1,, Nguyễn Văn Ba2, Nguyễn Đức Liên3, Nguyễn Thành Bắc1
1 Military Hospital 103, Vietnam Military Medical University
2 Center of Oncology - 103 Military Hospital
3 Tân Triều Brach of National Cancer Hospital

Main Article Content

Abstract

Objectives: To initially evaluate the results of treatment for high-grade glioma. Subjects and methods: A descriptive, prospective study on 52 high-grade glioma patients with indications for surgery, chemotherapy and radiotherapy at K Hospital, Tan Trieu campus, from January 1, 2019 to December 12. 2020. Results: Patients were predominantly male (61.5%) with a mean age of 45.2 years. Most patients had surgery to remove the maximum possible tumor (remove all and most of the tumor), accounting for 96.2%. Six months after surgery, the most commonly reported clinical symptoms were headache (55.8%), hemiplegia (21.2%), epileptic seizures (15.4%), sadness vomiting and vomiting (9.6%); blurred vision, reduced visual acuity (11.5%), the mean Karnofsky score is 67.7; assessment of objective response according to RECIST, 51 out of 52 patients achieved disease control rate (98.1%). Conclusion: Patients with high-grade glioma treated with surgery combined with chemotherapy and radiation gave relatively good results.  after 1 and 6 months after surgery, patients had a high rate of disease control in terms of objective response according to RECIST.

Article Details

References

1. Liang C, Jun S, Xiuzhi J, et al. (2014). Treating malignant glioma in Chinese patients: update on temozolomide. OncoTargets and Therapy, 7: 235–244.
2. Pang BC, Wan WH, Lee CK, et al. (2007). The role of surgery in high-grade glioma--is surgical resection justified? A review of the current knowledge. Ann Acad Med Singap, 36(5): 358-63.
3. A. R. Padhani, L. Ollivier (2001). The RECIST criteria: implications for diagnostic radiologists. The British journal of radiology, 74(887): 983-986.
4. Trần Kim Tuyến (2022), Nghiên cứu đột biến gen IDH1/2 của u tế bào thần kinh đệm lan tỏa ở người trưởng thành, Luận án tiến sĩ y học, Đại học Y Dược thành phố Hồ Chí Minh.
5. B. K. Rasmussen, S. Hansen, R. J. Laursen, et al. (2017). Epidemiology of glioma: Clinical characteristics, symptoms, and predictors of glioma patients grade I–IV in the the Danish Neuro-Oncology Registry. Journal of Neuro-oncology, 135(3): 571-579.
6. Stupp R, Mason WP, van den Bent MJ, et al (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 352, 987-996.
7. Senft C, Bink A, Franz K, et al (2011). Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol, 12 (11), 997-1003.
8. Antonio O, Kathryn B, Philip G, et al (2014). Phase II Study of Bevacizumab, Temozolomide and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma. Clin Cancer Res, 20(19), 5023–5031.